Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Issue Section
Date
Availability
1-20 of 27
Keywords: Survival
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
1
Sort by
Journal Articles
Subject Area:
Oncology
Journal:
Oncology Research and Treatment
Oncol Res Treat (2024) 47 (9): 401–409.
Published Online: 22 July 2024
..., metastasis site, serum LDH level, response to chemotherapy, and disease recurrence. Outcomes in LD-SCLC patients were found to be similar between sexes; median overall survivals in women compared to men was 18 versus 15 months, respectively ( p = 0.8). On the other hand, female patients with ED-SCLC had...
Journal Articles
Journal:
Oncology Research and Treatment
Oncol Res Treat (2023) 46 (12): 522–532.
Published Online: 14 November 2023
..., and survival outcomes of thymoma patients at least 80 years old and compare these features to those of patients younger than 80 years old. Method: Data from thymoma patients in the Surveillance, Epidemiology and End Results database between 2000 and 2019 were selected. Clinical features, treatment modalities...
Journal Articles
Qiaohui Zhan, Xuye Zhao, Guifeng Zheng, Jiahui Liu, Songling Wu, Jiawen Huang, Liuwen Yu, Fangmeng Fu
Journal:
Oncology Research and Treatment
Oncol Res Treat (2023) 46 (12): 512–521.
Published Online: 06 November 2023
...Qiaohui Zhan; Xuye Zhao; Guifeng Zheng; Jiahui Liu; Songling Wu; Jiawen Huang; Liuwen Yu; Fangmeng Fu Introduction: Although breast-conserving therapy (BCT) promises at least a similar survival rate for patients with early breast cancer compared with mastectomy, its efficacy in patients with human...
Journal Articles
Subject Area:
Topic Article Package: ADC (Antibody-Drug Conjugates)
,
Karger e-Journal Backfile Collection 2023
,
Oncology
Kriengsak Dhanaworavibul, Kittinun Leetanaporn, Panote Wattanapaisal, Kittiya Deevongkij, Chutinun Leelarujijaroen, Jitti Hanprasertpong
Journal:
Oncology Research and Treatment
Oncol Res Treat (2023) 46 (5): 192–200.
Published Online: 06 March 2023
...-free survival (DFS) and overall survival (OS). Compared with patients with an RHR ≤70 bpm, those with an RHR of 71–76 bpm had a 1.84- and 3.05-times higher likelihood of DFS ( p = 0.016) and OS ( p = 0.030), respectively, while those with RHR >76 bpm had a 2.20-times higher likelihood of DFS ( p...
Journal Articles
Subject Area:
Topic Article Package: ADC (Antibody-Drug Conjugates)
,
Karger e-Journal Backfile Collection 2023
,
Oncology
Journal:
Oncology Research and Treatment
Oncol Res Treat (2023) 46 (4): 157–164.
Published Online: 15 February 2023
...Carsten Nieder; Bård Mannsåker; Luka Stanisavljevic; Ellinor Haukland Introduction: Immune checkpoint inhibitors (ICIs) have become a mainstay of treatment for different cancer types. The purpose of this study was to evaluate patterns of care and overall survival (OS) after diagnosis of brain...
Journal Articles
Subject Area:
Oncology
Journal:
Oncology Research and Treatment
Oncol Res Treat (2022) 45 (12): 728–735.
Published Online: 15 June 2022
... included age at diagnosis, stage of disease, cause of death, interval time between BC and USC diagnosis, and overall survival. Results: The SEER database included 10,021 patients with USC during the years 1975–2015. 698 (6.96%) of these patients had been previously diagnosed with BC. The incidence of USC...
Journal Articles
Journal:
Oncology Research and Treatment
Oncol Res Treat (2022) 45 (1-2): 12–17.
Published Online: 18 November 2021
... the regimen as salvage therapy after disease progression from previous therapy. Sixty-five point six percentage of patients showed visceral metastases. The CBR was 31.2%, and the median progression-free survival (PFS) was 4.0 months (95% confidence interval [CI] 3.6–4.7). No grade 3–4 adverse events were...
Journal Articles
Subject Area:
Oncology
Ferhat Ferhatoglu, Fahmin Amirov, Berker Ozkan, Murat Kara, Alper Toker, Naziye Ak, Esra Aydın, Nail Paksoy, Dilek Yilmazbayhan, Adnan Aydiner
Journal:
Oncology Research and Treatment
Oncol Res Treat (2021) 44 (11): 590–601.
Published Online: 23 September 2021
... stage and is resistant to conventional chemotherapeutics. Due to the unique nature and rarity, we evaluated the epidemiological, clinicopathological, and survival data of PSC patients treated at our centre. Patients and Methods: We retrospectively collected demographic and clinical data of 67 PSC...
Journal Articles
Subject Area:
Oncology
Journal:
Oncology Research and Treatment
Oncol Res Treat (2021) 44 (7-8): 408–413.
Published Online: 21 July 2021
... of CRT, 6 of which were definitive. Surgery was either palliative ( n = 6) or radical ( n = 15). Results: After RT, the median overall survival (OS) was 10.4 months (m), median progression-free survival was 5.6 m, and median duration of local control (DOLC) was 8.9 m. There was a significant difference...
Journal Articles
Journal:
Oncology Research and Treatment
Oncol Res Treat (2021) 44 (5): 252–260.
Published Online: 28 April 2021
...-expressive group therapy (SEGT) can potentially benefit these patients. Objective: This systematic review and meta-analysis evaluated the effectiveness of SEGT for women with breast cancer, by focusing on survival, QoL, anxiety, and depression as outcomes. Methods: The Preferred Reporting Items...
Journal Articles
Journal:
Oncology Research and Treatment
Oncol Res Treat (2021) 44 (3): 76–85.
Published Online: 18 January 2021
... from June 2012 to July 2018. All analyses were done using SPSS 26. Results: 105 patients with treatment failure were included. After a median follow-up of 27 months (range 10–82), the 3-year survival rate after therapy failure was 19.4%. In multivariate analysis, squamous cell carcinoma antigen (SCC-Ag...
Journal Articles
Subject Area:
Oncology
Olaf Schoffer, Martin Roessler, Thomas Datzmann, Dimosthenis Andreou, Jens Jakob, Martin Eichler, Stephan Richter, Markus K. Schuler, Jochen Schmitt
Journal:
Oncology Research and Treatment
Oncol Res Treat (2021) 44 (3): 103–110.
Published Online: 30 December 2020
... of this article were (1) to investigate medical care and survival in STS and BS patients, and (2) to examine methodological aspects of corresponding analyses based on administrative healthcare data. Methods: We analyzed data from a statutory health insurance located in Saxony, Germany, covering approximately 2...
Journal Articles
Subject Area:
Oncology
Journal:
Oncology Research and Treatment
Oncol Res Treat (2021) 44 (1-2): 28–35.
Published Online: 11 December 2020
... in a population-based registry. Methods: A retrospective analysis of the Surveillance, Epidemiology, and End Results (SEER) database was conducted to compare the outcomes of thymoma patients with or without PORT. The primary outcomes were overall survival (OS) and cancer-specific survival (CSS). Conditional...
Journal Articles
Subject Area:
Oncology
Journal:
Oncology Research and Treatment
Oncol Res Treat (2020) 43 (12): 649–655.
Published Online: 12 October 2020
...Xiaoping Xia; Wenjing Jiang; Wencai Qi; Baoli Hong; Weidong Zhao Purpose: As a small-molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), apatinib has shown a survival benefit in multiple solid tumors. This study aims to evaluate the efficacy and safety...
Journal Articles
Subject Area:
Oncology
Journal:
Oncology Research and Treatment
Oncol Res Treat (2020) 43 (7-8): 362–371.
Published Online: 08 June 2020
... of modern immunohistochemistry (IHC)-based BC subtypes on long-term mortality. Method: We used a cohort of 200 women diagnosed with stage I–III BC in the period 1985–1990. Surgical samples underwent centralized pathology review. Multivariate models assessed associations of subtype with overall survival (OS...
Journal Articles
Subject Area:
Oncology
Abdullah Sakin, Suleyman Sahin, Nurgul Yasar, Cumhur Demir, Serdar Arici, Caglayan Geredeli, Sener Cihan
Journal:
Oncology Research and Treatment
Oncol Res Treat (2019) 42 (10): 506–514.
Published Online: 23 July 2019
...Abdullah Sakin; Suleyman Sahin; Nurgul Yasar; Cumhur Demir; Serdar Arici; Caglayan Geredeli; Sener Cihan Purpose: To determine whether hemogram parameters have prognostic effects on survival in patients with extensive-stage small cell lung cancer (ED-SCLC). Methods: This retrospective analysis...
Journal Articles
Subject Area:
Oncology
Serkan Keskin, Seden Küçücük, Naziye Ak, Banu Atalar, Murat Sarı, Hamdullah Sozen, Kamuran Ibis, Samet Topuz, Pınar Saip
Journal:
Oncology Research and Treatment
Oncol Res Treat (2019) 42 (3): 101–106.
Published Online: 19 January 2019
...%) cases, and there was extra-cranial disease in 11 (52%) cases. During the mean 86 months of follow-up, 18 of the patients (86%) died of the disease and 3 (14%) were alive with disease. The median survival time after the initial diagnosis of brain metastasis was 9 months. The median overall survival (OS...
Journal Articles
Subject Area:
Oncology
Tom van Cann, Jasmien Cornillie, Agnieszka Wozniak, Maria Debiec-Rychter, Raf Sciot, Daphne Hompes, Ignace Vergote, Patrick Schöffski
Journal:
Oncology Research and Treatment
Oncol Res Treat (2018) 41 (4): 206–213.
Published Online: 23 March 2018
...). The objective response rate to first-line palliative systemic therapy was 20% and the median progression-free survival was 4.9 months (range 0.1-17.1). The median survival from diagnosis of metastasis was 20.5 months (range 0.4-126.9). On multivariate analysis, metachronous disease, no progressive disease...
Journal Articles
Subject Area:
Oncology
Journal:
Oncology Research and Treatment
Oncol Res Treat (2017) 40 (12): 784–788.
Published Online: 29 November 2017
.... The majority were male (56%) and had distant metastases (74%). Chemotherapy was the major modality of treatment (86%) with a median overall survival (OS) of 33.3 weeks (range 1.7-245.4 weeks). Chemotherapy significantly (p < 0.001) improved OS in comparison to best supportive care only (37.6 vs. 13.9 weeks...
Journal Articles
Subject Area:
Oncology
Xiaoliang Wu, Zuan-Fu Lim, Zhongwen Li, Ling Gu, Wenjuan Ma, Qianghua Zhou, Huifang Su, Xing Wang, Xianzi Yang, Zhenfeng Zhang
Journal:
Oncology Research and Treatment
Oncol Res Treat (2017) 40 (6): 370–374.
Published Online: 10 May 2017
.... In addition, high expression of NORAD was correlated with larger tumor size (p = 0.021) and T stage (p = 0.045). Kaplan-Meier analysis indicated that patients with high NORAD expression had poor overall and disease-free survival (p < 0.001). Moreover, multivariate analysis showed that increased expression...
1